Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Who Dies From Prostate Cancer? An Analysis of the Surveillance, Epidemiology and End Results Database.

Roy S, Morgan SC.

Clin Oncol (R Coll Radiol). 2019 Sep;31(9):630-636. doi: 10.1016/j.clon.2019.04.012. Epub 2019 May 23.

PMID:
31130340
2.

Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis.

Shao YH, Kim S, Moore DF, Shih W, Lin Y, Stein M, Kim IY, Lu-Yao GL.

Eur Urol. 2014 Apr;65(4):693-700. doi: 10.1016/j.eururo.2013.05.023. Epub 2013 May 21.

3.

Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.

Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF 3rd, Choueiri TK, Taplin ME, Trinh QD, Feng FY, Nguyen PL.

Eur Urol. 2018 Aug;74(2):146-154. doi: 10.1016/j.eururo.2018.01.043. Epub 2018 Feb 22.

4.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
5.

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF, McLaren D, Parker CC, Parmar MKB, Ritchie AWS, Russell JM, Strebel RT, Thalmann GN, Mason MD, Sydes MR.

Eur Urol. 2015 Jun;67(6):1028-1038. doi: 10.1016/j.eururo.2014.09.032. Epub 2014 Oct 6.

6.

Diagnostic characteristics of lethal prostate cancer.

Helgstrand JT, Røder MA, Klemann N, Toft BG, Brasso K, Vainer B, Iversen P.

Eur J Cancer. 2017 Oct;84:18-26. doi: 10.1016/j.ejca.2017.07.007. Epub 2017 Aug 2.

PMID:
28779631
7.

Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.

Helgstrand JT, Røder MA, Klemann N, Toft BG, Lichtensztajn DY, Brooks JD, Brasso K, Vainer B, Iversen P.

Cancer. 2018 Jul 15;124(14):2931-2938. doi: 10.1002/cncr.31384. Epub 2018 May 3.

8.

Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.

Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schröder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1672-7. doi: 10.1111/j.1464-410X.2012.11434.x. Epub 2012 Aug 29.

9.

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.

Johnston TJ, Shaw GL, Lamb AD, Parashar D, Greenberg D, Xiong T, Edwards AL, Gnanapragasam V, Holding P, Herbert P, Davis M, Mizielinsk E, Lane JA, Oxley J, Robinson M, Mason M, Staffurth J, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Prescott S, Paul A, Powell P, Rosario D, Rowe E, Donovan JL, Hamdy FC, Neal DE; ProtecT study group.

Eur Urol. 2017 Mar;71(3):381-388. doi: 10.1016/j.eururo.2016.09.040. Epub 2016 Oct 6.

10.

The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma.

Wang J, Abudurexiti M, Shao N, Wei Y, Zhu Y, Ye DW.

Eur Urol Focus. 2018 Sep 11. pii: S2405-4569(18)30243-8. doi: 10.1016/j.euf.2018.08.024. [Epub ahead of print]

PMID:
30217630
11.

Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C Jr, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.

Eur Urol. 2019 Apr 13. pii: S0302-2838(19)30208-8. doi: 10.1016/j.eururo.2019.03.022. [Epub ahead of print]

PMID:
30992160
12.

Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer.

Mahal BA, Aizer AA, Efstathiou JA, Nguyen PL.

Cancer. 2016 Jan 1;122(1):78-83. doi: 10.1002/cncr.29691. Epub 2015 Sep 15.

13.

Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.

Hayman J, Phillips R, Chen D, Perin J, Narang AK, Trieu J, Radwan N, Greco S, Deville C Jr, McNutt T, Song DY, DeWeese TL, Tran PT.

Prostate. 2018 Jun;78(8):623-630. doi: 10.1002/pros.23507. Epub 2018 Mar 9.

PMID:
29520847
14.

Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.

Godtman RA, Holmberg E, Khatami A, Pihl CG, Stranne J, Hugosson J.

Eur Urol. 2016 Nov;70(5):760-766. doi: 10.1016/j.eururo.2016.03.048. Epub 2016 Apr 16.

PMID:
27090975
15.

Risk of lymph node metastases in pathological gleason score≤6 prostate adenocarcinoma: Analysis of institutional and population-based databases.

Wenger H, Weiner AB, Razmaria A, Paner GP, Eggener SE.

Urol Oncol. 2017 Jan;35(1):31.e1-31.e6. doi: 10.1016/j.urolonc.2016.08.004. Epub 2016 Sep 28.

PMID:
27692833
16.

Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.

Grytli HH, Fagerland MW, Fosså SD, Taskén KA.

Eur Urol. 2014 Mar;65(3):635-41. doi: 10.1016/j.eururo.2013.01.007. Epub 2013 Jan 14.

PMID:
23351721
17.

Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.

Gnanapragasam VJ, Lophatananon A, Wright KA, Muir KR, Gavin A, Greenberg DC.

PLoS Med. 2016 Aug 2;13(8):e1002063. doi: 10.1371/journal.pmed.1002063. eCollection 2016 Aug.

18.

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR.

Eur Urol. 2014 Sep;66(3):550-60. doi: 10.1016/j.eururo.2014.05.004. Epub 2014 May 16.

19.

Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.

Eur Urol. 2014 Jan;65(1):177-85. doi: 10.1016/j.eururo.2012.08.070. Epub 2012 Sep 7.

PMID:
22981136
20.

Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.

Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J.

Eur Urol. 2013 Jan;63(1):101-7. doi: 10.1016/j.eururo.2012.08.066. Epub 2012 Sep 5.

PMID:
22980443

Supplemental Content

Support Center